StockData
LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Lexeo Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.76+0.12 (+4.55%)

Close on Oct 19, 2026

Market cap
$236.33M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 4, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 12, 2026Before market open–$-0.30–
Q1 FY2026
Ended Mar 31, 2026
May 11, 2026Before market open–$-0.25–
Q4 FY2025
Ended Dec 31, 2025
Mar 30, 2026After market close–$-0.27–
Q3 FY2025
Ended Sep 30, 2025
Nov 5, 2025Before market open–$-0.33–
Q2 FY2025
Ended Jun 30, 2025
Aug 14, 2025Before market open–$-0.60–
Q1 FY2025
Ended Mar 31, 2025
May 12, 2025Before market open–$-0.99–
Q4 FY2024
Ended Dec 31, 2024
Mar 24, 2025Before market open–$-0.78–
Q3 FY2024
Ended Sep 30, 2024
Nov 13, 2024Before market open–$-0.89–
Q2 FY2024
Ended Jun 30, 2024
Aug 12, 2024Before market open–$-0.64–
Q1 FY2024
Ended Mar 31, 2024
May 9, 2024Before market open–$-0.77–
Q4 FY2023
Ended Dec 31, 2023
Mar 11, 2024After market close–$-0.86–

Press releases

Announcements Lexeo Therapeutics filed with the SEC